Oncology
Pancreatic Cancer Is Forcing Regulators to Move Faster
EMA has started a phased review of daraxonrasib in pancreatic cancer, while Revolution Medicines says its U.S. rolling NDA is nearing completion. The science is moving into the regulatory fast lane. Access systems are not ready yet.
Cervical Cancer Cannot Be Left Waiting at the Edge of the ADC Era
Do Not Turn Cancer Trials Into Political Collateral
ESC Cardio-Oncology 2026: Cancer therapy is getting smarter. Cardiac protection is still playing catch-up.
Gastric Cancer Gets a New Biomarker Access Signal
Prostate Cancer Access Moves Into the Veterans System
Cardio-oncology demand is rising, but training gaps are holding systems back
Prostate Cancer Access Moves Into the Veterans System
Gastric Cancer Gets a New Biomarker Access Signal
Metastatic Cancer Means Living With Loss Before the End
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.